MedPath

An evaluation study of decreasing effect of uncomfortable feelings in nose and eyes by consumption of plant extract

Not Applicable
Conditions
Healthy adult
Registration Number
JPRN-UMIN000030770
Lead Sponsor
CPCC Company Limited
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

(1) Subjects who have treated or taken medicine for perennial allergic rhinitis from 4 weeks before advance inspection to the end of the study. (2) Subjects who planning some treatment during the examination period. (3) Subjects who intake the medicines, the foods for specified health uses (FOSHU) and/or the health foods those are concerned their influence to test results. (4) Pregnant or expected pregnant, and lactating women. (5) Subjects who have previous and/or current medical history of serious disease in heart, liver, kidney. (6) Subjects who excessive alcohol intake. (7) Subjects who have smoking habit. (8) Subjects who have extremely irregular dining habits, and subjects who have midnight work or irregular shift work. (9) Subjects who have previous medical history of drug and/or food, allergy, especially for Shiso leaf. (10) Subjects who are participating the other clinical tests. Subjects who participated within 4-weeks prior to the current study and/or who plan to participate the other clinical tests. (11) Subjects who donated over 200mL blood and/or blood components within the last one month to the current study. (12) Subjects who donated over 400mL blood and/or blood components within the last three month to the current study. (13) Females who donated over 400mL blood and/or blood components within the last four month to the current study. (14) Males who will be collected over 1200mL blood and/or blood components, when the sampling amounts within the last twelve month are adding to the planned sampling amounts of this study. (15) Females who will be collected over 800mL blood and/or blood components when, the sampling amounts within the last twelve month are adding to the planned sampling amounts of this study. (16) Others who have been determined ineligible by principal investigator or sub-investigator.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath